According to Turkish media reports, Turkey began final Phase III trials of an experimental Chinese coronavirus vaccine on 16 September 2020, Reuters news agency reported on Wednesday.
This vaccine will be administered to 1,200 to 1,300 health workers over 10 days and a second dose will be given 14 days after the first, broadcasters CNN Turk and Haberturk reported, with the results of the trial sent the World Health Organisation (WHO).
The broadcasters added that the vaccine candidate will later be administered to volunteers with chronic diseases, with the aim of vaccinating 13,000 people.
According to Reuters, Turkey's health ministry did not comment on the reports, however, Health Minister Fahrettin Koca is due to hold a news conference later on 16 September.
Koca had announced that Phase III work had started on the Chinese vaccine candidate, as well as another developed by Pfizer. Russia's application to conduct Phase III trials in Turkey for its experimental vaccine was being evaluated and a decision would likely be made this week, he had said.
China launched a vaccine emergency use programme in July 2020, offering three experimental shots developed by a unit of state pharmaceutical giant China National Pharmaceutical Group (Sinopharm) and US-listed Sinovac Biotech. A fourth COVID-19 vaccine being developed by CanSino Biologics was approved for use by the Chinese military in June.
Broadcaster Haberturk added that the vaccine candidate on trial in Turkey was developed by Sinovac.
Pfizer and BioNTech granted FDA approval for XFG-adapted COVID-19 vaccine
4basebio announces strategic collaboration with Genezen
Charles River and Medigen collaborate on next-generation enterovirus vaccine development
Innorna Nominated for 2026 Prix Galien USA Best Startup Award
Sanofi's MenQuadfi receives EU approval for infants from six weeks
Evaxion to present three-year cancer vaccine data at ESMO Congress 2026
Evaxion presents new preclinical data on cytomegalovirus vaccine EVX-V1
Northwest Biotherapeutics presents on propensity score matching at BNOS 2026
Taiwan biomedical startups hold over 100 business meetings at BIO 2026
SK bioscience to lead Gates Foundation-funded ROTOR project
Anixa Biosciences' breast cancer vaccine technology granted first Korean patent
Transgene expands myvac platform into non-small cell lung cancer with TG4070
Replicate Bioscience awarded Gates Foundation grant to advance srRNA vaccine candidates for TB